US biotechnology firms Biogen Idec and Genentech, which is majority-owned by Swiss drug major Roche, have submitted a supplemental Biologics License Application to the Food and Drug Administration for the use of Rituxan (rituximab) as first-line treatment of previously-untreated patients with low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in combination with cyclophosphamide, vincristine and prednisone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy or following CVP chemotherapy in those patients who achieved a response of stable disease or better.
The submission is primarily based on efficacy and safety data from two randomized, controlled studies of Rituxan in 644 previously-untreated patients, the first of which was a Phase III 322-patient trial in follicular, CD20-positive, B-cell NHL that met its primary endpoint of an improvement in progression-free survival in combination with CVP chemotherapy versus CVP chemotherapy alone.
Rituxan is already approved as a single agent for patients with relapsed or refractory, low-grade or follicular CD20-positive, B-cell NHL. The drug, in combination with CHOP or other anthracycline-based chemotherapy, was approved in February as first-line treatment for patients with diffuse large B-cell lymphoma. It is also cleared in combination with methotrexate to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze